CD19 and myasthenia gravis: Studies have also shown that the proportion of CD19+BAFFR+ cells in patients with MG increased, while the proportion of CD19+BAFFR+ cells in patients with MG decreased after taking TAC, which was correlated with the improvement of clinical symptoms (14, 23).